Iwona Piątek

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Adalimumab is a subcutaneously administered recombinant fully human monoclonal antibody targeting tumor necrosis factor alpha. It has been approved for use in Poland to treat patients with Crohn's disease under the program of Polish National Health Found since 2010. AIM The aim of this study was to evaluate the efficacy of adalimumab monotherapy for(More)
  • 1